Research article | Open | Published:
Cheiradone: a vascular endothelial cell growth factor receptor antagonist
BMC Cell Biologyvolume 9, Article number: 7 (2008)
Angiogenesis, the growth of new blood vessels from the pre-existing vasculature is associated with physiological (for example wound healing) and pathological conditions (tumour development). Vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) are the major angiogenic regulators. We have identified a natural product (cheiradone) isolated from a Euphorbia species which inhibited in vivo and in vitro VEGF- stimulated angiogenesis but had no effect on FGF-2 or EGF activity. Two primary cultures, bovine aortic and human dermal endothelial cells were used in in vitro (proliferation, wound healing, invasion in Matrigel and tube formation) and in vivo (the chick chorioallantoic membrane) models of angiogenesis in the presence of growth factors and cheiradone. In all cases, the concentration of cheiradone which caused 50% inhibition (IC50) was determined. The effect of cheiradone on the binding of growth factors to their receptors was also investigated.
Cheiradone inhibited all stages of VEGF-induced angiogenesis with IC50 values in the range 5.20–7.50 μM but did not inhibit FGF-2 or EGF-induced angiogenesis. It also inhibited VEGF binding to VEGF receptor-1 and 2 with IC50 values of 2.9 and 0.61 μM respectively.
Cheiradone inhibited VEGF-induced angiogenesis by binding to VEGF receptors -1 and -2 and may be a useful investigative tool to study the specific contribution of VEGF to angiogenesis and may have therapeutic potential.
Angiogenesis, the growth of new blood vessels from the existing vasculature is associated with physiological (wound healing, endometrial cycle and embryonic development) and pathological processes (tumour growth, rheumatoid arthritis, diabetic retinopathy, and brain and cardiac infarctions) [1, 2]. Angiogenesis is mediated by pro-angiogenic factors including vascular endothelial cell growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiopoietin, and epidermal growth factor (EGF) [3–6].
VEGF comprises a family of multifunctional cytokines which include the variants VEGF-A, -B, -C, -D and-E and placental growth factor (PlGF) [7, 8]. VEGF-A is mitogenic in vitro and angiogenic in vivo [9, 10] and its role in angiogenesis and vasculogenesis has been elucidated [11–13]. At least nine different isoforms of human VEGF-A have been identified with 121, 145, 148, 162, 165, 183, 189 and 206 amino acid residues [14, 8]. Of these, VEGF165 is most clearly associated with pathological angiogenesis  and exerts its biological action upon binding with two high affinity receptor tyrosine kinases; VEGFR-1 (flt-1) and VEGFR-2 (kinase domain receptor; flk-1) [8, 15]. The role of these receptors, especially flk-1 in angiogenesis has been confirmed through gene knockout studies and flk-1-/- embryos are unable to form blood islands and to generate haematopoietic precursors [reviewed in ]. VEGFR-1 has a 50 times higher binding affinity for VEGFR-1 than VEGFR-2  however, VEGFR-2 has a stronger receptor tyrosine kinase activity than VEGFR-1 and acts as a major mitogenic receptor on endothelial cells (ECs) [16, 18].
Due to the central role of angiogenesis in tumour growth and progression it has been a target in cancer therapy. For example Bevacizumab, a VEGF-A blocking antibody has been approved for the treatment of metastatic colorectal cancer  and Sunitinib, a VEGF receptor antagonist for treatment of gastrointestinal stromal tumours and for advanced renal cell carcinoma . Several other VEGF inhibitors including the receptor tyrosine kinase inhibitors (RTKIs), Pegaptanib and Sorafenib have been tested in phase-1 to phase-III clinical trials against VEGF-associated malignancies [21, 22].
Natural compounds from medicinal plants display diverse pharmacological activities  and have advantages over synthetic drugs, such as smoother action, better tolerance and fewer allergic reactions. Cheiradone, a naturally occurring plant diterpene, was isolated from the medicinal plant Euphobia chiradenia and in preliminary screening was shown to be a PLA2 inhibitor, have anti-inflammatory properties and inhibit wound healing although the mechanisms of action were not investigated .
In this study we have investigated the effect of cheiradone on VEGF-induced angiogenesis and show VEGF165 binding to VEGFR-1 and -2 resultined in inhibition of in vitro and in vivo angiogenesis.
Cheiradone inhibited VEGF165 binding to VEGFR-1 and -2
Cheiradone was found to specifically inhibit the binding of VEGF165 to VEGFR-1 and VEGFR-2 in a dose dependent manner with IC50 values of 2.9 ± 0.31 μM and 0.61 ± 0.14 μM respectively (Figure 1; Table 1). No significant inhibition of FGFR-1 and -2 was observed even at the highest concentration (328.20 μM) tested (data not included).
Cheiradone inhibited VEGF-induced EC proliferation
Cheiradone was tested to evaluate its effect on cell proliferation in the presence of VEGF, EGF and FGF-2. A concentration-dependent inhibition of VEGF-stimulated BAEC and HDMEC proliferation with IC50 values of 7.4 ± 0.74 and 7.8 ± 1.2 μM respectively (p < 0.005) (Figure 2; Table 1) was observed. However, no significant inhibition of FGF-2- and EGF-triggered cell proliferation was observed (data not included).
Cheiradone inhibited VEGF-induced EC Migration
The effect of cheiradone on the migration of ECs was analysed using both two- and three-dimensional cell migration assays. In the two-dimensional assay, a wound-healing model was used to assess the migratory behaviour of BAECs and HDMECs (Figure 3). In the VEGF treated control group, significant wound healing was found 24 h after the cell monolayer was wounded with a sterile razor blade (Figure 3Biv; results shown for HDMEC). No significant inhibition was observed on non-stimulated wound recovery (Figure 3Biii) However, VEGF- stimulated HDMEC and BAEC migration was inhibited after 24 h in a dose dependent manner by cheiradone with IC50 values of 6.5 ± 0.97 and 7.1 ± 0.77 μM respectively (p < 0.05; Figure 3A and 3Bv). In a three-dimensional cell migration assay, BAECs and HDMECs treated with VEGF showed 2.8 and 2.5 fold increase in migration to the lower chamber compared to non-treated cells respectively (Figure 3C). Cheiradone was found to significantly inhibit (p = 0.001 in each case) VEGF-induced BAEC and HDMEC migration with IC50 values of 7.5 ± 0.92 and 5.2 ± 0.38 μM respectively.
Cheiradone had no effect on FGF-2 or EGF stimulated migration in the concentration range used (results not shown).
Cheiradone inhibited VEGF-induced EC tube formation
To examine the role of cheiradone on EC differentiation into vascular structures in vitro, tube formation of BAECs and HDMCs on Matrigel was assessed. When these cells were stimulated with VEGF, elongated tube-like structures were formed and the process was inhibited in a dose dependent manner by cheiradone (Figure 4A). Cheiradone reduced the width and length of VEGF-induced HDMEC and BAEC tubes with IC50 values of 6.0 ± 0.38 and 7.7 ± 1.5 μM respectively (p < 0.005; Fig 4Bi–iv, results are shown for HDMEC). No significant effect of cheiradone was seen on non-stimulated tube formation (Figure 4Bii).
Cheiradone inhibited cell invasion
The effect of cheiradone on cell invasion was analysed using a Transwell Boyden chamber system coated with reconstituted growth factor-reduced Matrigel. BAECs or HDMECs were allowed to invade the lower chamber in the presence and absence of VEGF and cheiradone. A statistically significant increased in cell invasion was observed in VEGF treated HDMECs (2.2 fold, p = 0.002) and BAECs (3.3 fold, p = 0.001) (Figure 5). Cheiradone showed dose-dependent inhibition of VEGF stimulated cell invasion of HDMEC and BAEC with IC50 values of 8.3 ± 1.0 and 6.3 ± 0.31 μM respectively (p < 0.05).
Cheiradone inhibited angiogenesis in the CAM assay
The above in vitro data suggests that cheiradone inhibits several steps of angiogenesis in vitro. Therefore, we analyzed its effect on in vivo angiogenesis using the CAM assay. After exogenous stimulation of angiogenesis with VEGF165, significant new blood vessel growth was observed towards the stimulus after 6 days (Figure 6C, m = 3, n = 5). There was no significant angiogenic response to cheiradone alone (Fig 6B, m = 0.5, p = 0.0875, n = 5). VEGF165-induced blood vessels formation was completely abolished in the presence of cheiradone (m = 0, n = 5, p = 0.0001) (Figure 6D). There was no evidence of an inflammatory response with cheiradone alone (Fig 6) or in the control (Figure 6A).
No significant cytotoxicity was found at the tested concentrations of cheiradone (Figure 7A), whereas staurosporine induced a noticeable cytotoxic effect in the MTT (Figure 7B) and immunofluorescence (Figure 7D) assays.
Sesterterpenes are naturally occurring polyisoprene compounds widely distributed in plants and animals. There is growing interest in these molecules as potential disrupters of protein-protein interactions  since many protein interfaces are characterised by extended, flat surfaces and a number of small molecules which interfere with protein-protein binding have been identified . In addition, members of the sesterterpene family have moderate antibacterial activity against Mycobacterium tuberculosis strain H(37)Rv, inhibit DNA replication , are cytotoxic against tumour cell lines  and have potent antiplasmodial properties .
During angiogenesis, nascent blood vessels grow by sprouting from the existing vasculature by a cascade of events including degradation of the basement membrane, EC migration, proliferation and tube formation . VEGF exerts its angiogenic effect by binding to high affinity receptors on EC. In addition other growth factors, FGF-2 and EGF and their corresponding receptors are associated with angiogenesis .
In this study, we demonstrated that cheiradone inhibited multiple steps of VEGF-induced angiogenesis in vitro and in vivo. VEGF is the main regulator of angiogenesis and elevated levels have been reported in pathological conditions. The binding of VEGF to high affinity tyrosine kinase receptors such as VEGFR-1 & 2 activates VEGF-dependent signalling cascades which initiate the early events of angiogenesis (cell proliferation and migration from the lumen of existing vessels). Our in vitro inhibition data showed that cheiradone appeared to inhibit EC proliferation and migration with IC50 values in the range 5.2–7.8 μM. In the later stages of angiogenesis, ECs differentiate into tubular like structures that eventually form the lumen of the new vessel. The in vitro Matrigel tube formation assay showed that cheiradone inhibited VEGF-induced tube-like structures at low concentrations. We also demonstrated that cheiradone completely inhibited angiogenesis in vivo using the CAM assay. Therefore, cheiradone appears an effective antagonist of angiogenesis. Cheiradone was equally effective at inhibiting angiogenesis in both large vessel-derived (BAEC) and small vessel-derived cells (HDMEC; the in vivo target of angiogenic modulators).
Binding studies with VEGFR-1 and -2 showed significant inhibition of VEGF binding in the presence of cheiradone, with stronger inhibition of VEGFR-2. When cells were pre-incubated with cheiradone, and the cheiradone removed prior to addition of VEGF a significant inhibition of cell proliferation was still observed, indicating that cheiradone was not interacting directly with VEGF. Instead cheiradone competed with VEGF for binding to a VEGF receptor. Both VEGFR-1 and -2 contain extracellular, juxtamembrane and tyrosine kinase domains. We have no evidence which domain cheiradone binds to and are currently investigating the tyrosine kinase activity of the VEGF receptors in the presence of the inhibitor. An additional mechanism by which cheiradone can affect VEGF-induced angiogenesis is by regulating the expression levels of VEGFR-1 and/or VEGFR-2. We are currently investigating the interaction of cheiradone with the receptors on endothelial cells.
Semino et al.,  have developed an in vivo model of angiogenesis in the presence of interstitial flow. They propose a two step model of angiogenesis requiring initial activation by VEGF and subsequent maturation of the new blood vessel on exposure to EGF. Cheiradone would be an ideal molecule to test this model since it has no activity against EGF. In vivo, VEGFR-1 is constitutively expressed in the blood vascular system while VEGFR-2 is down regulated but is over expressed in angiogeneic endothelial cells and after hypoxia . We have shown that cheiradone is more active against VEGFR-2 and may therefore be a more specific molecule for targeting angiogenic blood vessels in diseases such as cancer.
In addition, cytotoxicity studies showed that cheiradone had no adverse effects at concentrations greater than those used in the present study.
The advantage of cheiradone over existing VEGF inhibitors is that it does not remove VEGF from the system and VEGF activity may be modulated by varying the concentration of cheiradone.
We have demonstrated that cheiradone, a naturally occurring sesterterpene inhibits VEGF-induced angiogenesis by competing with VEGF for VEGFR-1 and -2. There was no activity against FGF-2 or EGF. Further study of the structural relationships of cheiradone and its activity may provide a basis for designing VEGF receptor antagonist with enhanced inhibitory potential and improved specificity.
Matrigel (Becton Dickinson, UK), FGF-2, goat anti-active caspase-3 antibody (R&D System), VEGF165 (Apollo Cytokine Research, Cambridge, UK), EGF, VEGFR-1 and -2 and FGFR-1 and -2, anti-FGF-2 and anti-VEGF antibodies (Santa Cruz Biotechnology, Heidelberg, GDR), ABTS peroxidase substrate kit (Vector, UK), Transwell chamber system, culture plates and flasks (SLS, UK), anti-goat Alexa flour 488 conjugated green fluorescence dye and other chemical of commercial grade were purchased from Sigma (Poole, UK).
Human dermal microvascular endothelial cells (HDMECs) and the appropriate medium were purchased from TCS Cellworks (Buckingham, UK) and were cultured and maintained according to the supplier's instructions. Bovine aortic endothelial cells (BAECs) were from an established large vessel primary cell culture obtained and characterised as described previously . They were routinely cultured in Dulbecco's modified Eagles medium (DMEM) containing varying concentrations of foetal calf serum (FCS). All cells were used between passages six to nine.
Cell proliferation assay
Cells were seeded in triplicate at a concentration of 2.5 × 104/ml, in 2 ml of complete medium in 6-well plates. After attachment (24 h), medium was replaced with serum poor medium (SPM), containing 2.5% foetal calf serum in which the cells grew at a significantly reduced rate. Growth factors FGF-2 and EGF (25 ng/ml), and VEGF165 (10 ng/ml) with and without the test compound at different concentrations was added and cells incubated for a further 72 h. Control wells were treated with 5 μl DMSO. Concentration ranges of test compounds and pre-incubation times were based on pilot studies. MTT and immunofluorescence studies using active caspase-3 as a measure of apoptosis confirmed that test compounds were not cytotoxic at the concentrations used (see below). After 72 h, cells were washed in PBS, detached in 0.05%w/v trypsin in PBS, and counted on a Coulter counter (Coulter Electronics, Hialeah, FL) set to a threshold of 30 μm. Experiments were performed at least twice in triplicate wells and significance was determined by the Student t test. A representative example is shown.
Cell migration assay
Cell migration was examined in vitro using a Transwell chamber system with 8.0 μm pore polycarbonate filter inserts (TSL, UK). The Transwell insert was coated overnight with 0.1%w/v gelatine, and air-dried. Cells (1 × 105) were placed in the upper part of the filter and test compounds at different concentrations with and without growth factors were added to the lower part in SPM. Cells were incubated at 37°C for 16 h. After fixation (4% paraformaldehyde), and staining (Geimsa), cell migration in duplicate wells was determined by counting cell numbers on the lower surface. Experiments were performed at least twice and a representative example is shown. Significance was determined by the Student t test.
Wound healing assay
Cells (6 × 104/ml) were added to a Thrermanox cover slip in a 24-well plate in complete medium and incubated for 24–48 h. When confluent, the medium was replaced with DMEM containing 0.1% FCS and incubated for a further 48 h. Cover slips were washed (PBS, ×3), wounded with a sterile razor to produce a straight edged cut and washed in PBS to remove dislodged cells. Cover slips were added to a fresh 24-well plate in 0.1% FCS and incubated with VEGF165 or the other growth factors and a range of concentrations of test compound for 24 h. Under these conditions there was negligible proliferation but measurable migration. Slides were fixed in ethanol (100%), stained with methylene blue and photographed. For each slide, 10 fields of view (2 mm × 1.45 mm) were counted at random. Each experiment was performed at least twice and significance was determined by the Student t test.
Cell differentiation assays in Matrigel
Cells (1.0 × 106/ml) were mixed with an equal volume of Matrigel at 4°C. Aliquots (45 μl) were added to the wells of a 48-well plate and allowed to polymerise (1 h) when 500 μl of microvascular endothelial cell medium containing VEGF165 or the other growth factors, with or without the test compound was added. The cells were incubated for 24 h at 37°C then fixed in 4% paraformaldehyde (5 min), washed in cold ethanol and air dried. Cells were stained with Geimsa (30 sec), air dried and photographed. Ten random fields were selected and the number of closed tubes counted.
All experiments were performed in triplicate and repeated at least twice and significance was determined by the Student t test.
A Transwell cell culture chamber with 6.5-mm-diameter polycarbonate filters (8-μm pore size) were coated with 30 μg/ml Matrigel. Cells (1 × 105) were added to the upper chamber suspended in an appropriate medium. The medium containing a range of concentrations of test compound was added to the lower chamber in the presence and absence of VEGF165 or the other growth factors. After 24 h incubation at 37°C, the medium from the lower chamber was removed, cell fixed (4% paraformaldehyde) and stained. The number of cells invaded to the lower chamber through the Matrigel was counted under phase-contrast microscopy. Each invasion experiment was performed in triplicate and repeated at least twice. Statistical significance was determined using the Student t test.
Competition between growth factors, their cell surface receptors and test compounds was assessed as described previously . A 96-well plate was coated overnight with growth factors (2 μg/ml of VEGF165 or FGF-2) and blocked with 1% BSA in PBS containing 0.05% Tween-20. The test compound was separately pre-mixed with soluble receptors VEGFR-1, VEGFR-2, FGFR-1 or FGFR-2 (2 μg/ml in each case) for 2 h and added to the plate and incubated for a further 2 h. The plate was washed (×3 with PBS-Tween-20) and incubated with anti-VEGF or anti-FGF-2 antibody (1:500 in PBS-Tween-20) for 45 min, washed and incubated with horseradish peroxidase conjugated goat anti-IgG (Santa Cruz, 1:1000) for a further 45 min. After washing (×3), ABTS peroxidase substrate (Vector, UK) was added and the absorbance read at 405 nm. IC50 values were calculated from the data using the EZ-Fit enzyme kinetic software (Perella Scientific Inc., Amherst, USA).
Chick chorioallantoic assay
The angiogenic activity of cheiradone was determined using the semi-quantitative chick chorioallantoic assay (CAM) as described previously . To expose the CAM a window was created in the shells of 4 day-old chicken eggs. On day 8, a 2 mm3 methycellulose pellet (5 μl of 1% sterile methylcellulose; 400 centipoise, Sigma UK) containing no additions (control), the test compound (10 μg) with and without VEGF (100 ng) were applied to the membrane. The resultant angiogenesis scored on day 14 as 0- negative; 0.5- change in vessel architecture; 1- partial spokewheel (1/3 of circumference exhibits directional angiogenesis); 2- spokewheel; 3 or greater-strong and fully spokewheel. This approach enabled calculation of an accumulated response in each group. To photograph the membrane, 2 cm3 of a 50% emulsion of aqueous paraffin oil containing 2% Tween-80 was injected at the site of application and photographed using a Leitz dissecting microscope. Each experiment was performed five times and statistical significance was determined by the Mann-Whitney U test and the data is expressed as a median value (m).
Cheiradone toxicity was determined using MTT and active caspase-3 assays. BAECs or HDMECs (7.5 × 103) were seeded in a 96 well plate and incubated for 4 h to allow cell adhesion. Cheiradone or staurosporine, an inducer of active caspase-3 and therefore, of apoptosis (1 μM) was added to the wells. Control cells were treated with PBS and the plate was incubated at room temperature for 72 hours. MTT reagent (10 μl) was added followed by incubation at room temperature for 2–4 h. When a purple precipitate was visible, detergent reagent (100 μl) was added to the plates and incubated at room temperature for 2 h in the dark. Absorbance was measured at 570 nm using a microplate reader.
In the apoptosis assay, HDMECs or BAEC (4 × 104/ml) in complete medium were added to the chambers slide and allowed to adhere for 24 h. Cheiradone (8.2 μM) or staurosporine (1 μM) were added to all wells except control (PBS) and incubated for 24 hours. Wells treated with staurosporine were immediately washed (PBS) and fixed (4% paraformaldehyde) when cell morphology became round (2–4 h). After washing and fixing, cells were permeablized (0.1% Triton X-100; 10 min), washed (×5 ~ 5 min each), air dried and blocked with 1% BSA in 1:50 TBS Tween for 1 h at room temperature. Cells were incubated with goat anti-active caspase-3 (R&D system, UK; 1% BSA in TBS Tween) for 1 h. The plates were incubated with anti-goat Alexa-Flour 488 conjugated green fluorescent dye for 1.5 h at room temperature. Ten random homogeneous fields were viewed, and photographed.
Folkman J: Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007, 6: 273-86. 10.1038/nrd2115.
Hillen F, Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007 Aug 24,
Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995, 1: 182-193.
Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G, Imamura M: TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol. 2000, 17: 453-460.
Milkiewicz M, Ispanovic E, Doyle JL, Haas TL: Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell iol. 2006, 38: 333-357. 10.1016/j.biocel.2005.10.006.
Morisada T, Kubota Y, Urano T, Suda T, Oike Y: Angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium. 2006, 13: 71-79. 10.1080/10623320600697989.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669.
Takahashi H, Shibuya M: The vascular endothelial growth factor VEGF/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005, 109: 227-241.
McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN, Bouchier-Hayes DJ: Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol. 2001, 27: 714-718. 10.1053/ejso.2001.1177.
Parenti A, Bellik L, Brogelli L, Filippi S, Ledda F: Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004, 286: H1978-1984. 10.1152/ajpheart.00414.2003.
Liang D, Chang JR, Chin AJ, Smith A, Kelly C, Weinberg ES, Ge R: The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis and hematopoiesis in zebrafish development. Mech Dev. 2001, 108: 29-43. 10.1016/S0925-4773(01)00468-3.
Nagy JA, Dvorak AM, Dvorak HF: EGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med. 2003, HKJ: 169-175. 10.1016/S1050-1738(03)00056-2.
Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G: Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat Med. 2004, 10: 950-958. 10.1038/nm1097.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004, 56: 549-580. 10.1124/pr.56.4.3.
Eming SA, Krieg T: Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc. 2006, 11: 79-86. 10.1038/sj.jidsymp.5650016.
Shibuya M: Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006, 9: 225-230. 10.1007/s10456-006-9055-8.
Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Lain G, Gionnet K, Goncalves M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A: Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth factor inhibitor. J Biol Chem. 2003, 12;278: 35564-35573. 10.1074/jbc.M304435200.
Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005, 9: 777-794. 10.1111/j.1582-4934.2005.tb00379.x.
Kramer I, Lipp HP: Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007, 32: 1-14. 10.1111/j.1365-2710.2007.00800.x.
Schneider Bryan, Sledge George: Drug Insight: VEGF as a therapeutic target for breast cancer. Nature Clinical Practice Oncology. 2007, 4: 181-189. 10.1038/ncponc0740.
Cabebe E, Fisher GA: Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic ccancer. Expert Opin Investig Drugs. 2007, 16: 467-476. 10.1517/135437126.96.36.1997.
Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007, 12: 191-200. 10.1634/theoncologist.12-2-191.
Lovkova M, Ya GN, Buzuk SM, Sokolova NI, Kliment'eva : Chemical Features of Medicinal Plants (Review). Applied Biochemistry and Microbiology. 2001, 37: 229-237. 10.1023/A:1010254131166.
Abbas M, Jassbi AR, Zahid M, Ali Z, Alam N, Akhtar F, Iqbal Choudhary M, Ahmad Uddin Viqar: Three new diterpenoids from Euphorbia cheiradenia. Helvetica Chimica Acta. 2000, 83: 2751-2755. 10.1002/1522-2675(20001004)83:10<2751::AID-HLCA2751>3.0.CO;2-B.
Schade M, Oschkinat H: NMR fragments screening: tackling protein-protein interaction targets. Curr Opin Drug Discovery Dev. 2005, 8: 365-373.
Eyckerman S, Lemmens I, Catteeuw D, Verhee A, Vandekerckhove J, Lievens S, Tavernier : Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat Methods. 2005, 2: 427-433. 10.1038/nmeth760.
Choi HJ, Choi YH, Yee SB, Im E, Jung JH, Kim ND: Incinin-1 induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cell lines. Mol Carcinog. 2005, 44: 162-173. 10.1002/mc.20084.
Petit GR, tan R, Cichacz ZA: Antineoplastic agent 542. Isolation and structure of sesterstatin from the Indian Ocean sponge Hyrtios erecta. J Nat Prod. 2005, 68: 1253-1255. 10.1021/np0402221.
Kirsch G, Kong GM, Wright AD, Kaminsky R: A new bioactive sesterterpene and antiplasmodial alkaloid from the marine sponge hyrtios cf. erecta. J Nat Prod. 2000, 63: 825-829. 10.1021/np990555b.
Klagsprun M, Folkman J: Peptide growth factors and their receptors. Edited by: Sporn MB, Roberts AB. 1990, Springer, NY, 549-586.
Dunn I, Heese O, Blach P: growth factors in glioma angiogenesis: FGFs, PDGF, EGF and TGFs. J Neuro-Oncol. 2000, 50: 121-137. 10.1023/A:1006436624862.
Semino CE, Kamm RD, Lauffenberger DA: Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis by VEGF under interstitial flow. Exp Cell Res. 2006, 312: 289-298.
Otrock Z, Makarem J, Shamseddine A: Vascular endothelial growth factor family of ligands and receptors:Review. Bllod cells, Molecules and Diseases. 2007, 38: 258-268. 10.1016/j.bcmd.2006.12.003.
Duraisamy Y, Slevin M, Smith N, Bailey J, Zweit J, Smith C, Ahmed N, Gaffney J: Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing. Angiogenesis. 2001, 4: 277-288. 10.1023/A:1016068917266.
Ifat S, Tamer L, Mink S, Noam A, shivani C, Dietmar S, Dina R: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2003, 275: 34881-34886.
West DC, Thompson WD, Sellls PG, Burbridge MF: Angiogenesis assays using the chick chorioallantoic membrane. In Methods in molecular medicine-Angiogenesis: Reviews and Protocols. Edited by: Murray JC. 2001, Humana Press, 107-130.
We would like to thank the Research Institute of Health and Social Care of Manchester metropolitan University for funding for SJ and M Hoult for assistance in the preparation of the manuscript.
SH carried out the angiogenic assays.
JG, NA and MS participated in the design of the study and preparation of the manuscript. MM, MC and AE isolated and characterised the cheiradone.
SM carried out the experiments on tube formation DW performed the CAM assay. All authors read and approved the manuscript.
Authors’ original submitted files for images
About this article
- Vascular Endothelial Cell Growth Factor
- Vascular Endothelial Cell Growth Factor Receptor
- Vascular Endothelial Cell Growth Factor
- Vascular Endothelial Cell Growth Factor Inhibitor
- Human Dermal Microvascular Endothelial Cell